Daiichi Sankyo, which has struggled financially since losing exclusivity for its blood pressure drug Benicar, is again swinging the job-cutting ax in the U.S., eliminating 280 jobs from its commercial operations.Original Article
Daiichi Sankyo takes another big whack at U.S. sales operations, cutting 280 jobs
